EVAX vs. CASI, CSBR, BCAB, TIL, PASG, ATRA, ENTX, DYAI, CVM, and AVRO
Should you be buying Evaxion Biotech A/S stock or one of its competitors? The main competitors of Evaxion Biotech A/S include CASI Pharmaceuticals (CASI), Champions Oncology (CSBR), BioAtla (BCAB), Instil Bio (TIL), Passage Bio (PASG), Atara Biotherapeutics (ATRA), Entera Bio (ENTX), Dyadic International (DYAI), CEL-SCI (CVM), and AVROBIO (AVRO). These companies are all part of the "medical" sector.
Evaxion Biotech A/S (NASDAQ:EVAX) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends.
CASI Pharmaceuticals received 182 more outperform votes than Evaxion Biotech A/S when rated by MarketBeat users. However, 58.06% of users gave Evaxion Biotech A/S an outperform vote while only 51.28% of users gave CASI Pharmaceuticals an outperform vote.
11.0% of Evaxion Biotech A/S shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 41.6% of Evaxion Biotech A/S shares are held by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Evaxion Biotech A/S presently has a consensus target price of $11.00, suggesting a potential upside of 218.84%. CASI Pharmaceuticals has a consensus target price of $6.00, suggesting a potential upside of 65.29%. Given Evaxion Biotech A/S's higher possible upside, research analysts clearly believe Evaxion Biotech A/S is more favorable than CASI Pharmaceuticals.
Evaxion Biotech A/S has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -105.76%. CASI Pharmaceuticals' return on equity of -110.11% beat Evaxion Biotech A/S's return on equity.
In the previous week, Evaxion Biotech A/S had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 3 mentions for Evaxion Biotech A/S and 2 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.97 beat Evaxion Biotech A/S's score of 0.40 indicating that CASI Pharmaceuticals is being referred to more favorably in the news media.
Evaxion Biotech A/S has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Evaxion Biotech A/S has higher earnings, but lower revenue than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.
Summary
Evaxion Biotech A/S beats CASI Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Evaxion Biotech A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evaxion Biotech A/S Competitors List
Related Companies and Tools
